The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages 146-150

  Kniepeiss, Daniela ^a   Renner, Wilfried ^b   Trummer, Olivia ^b   Wagner, Doris ^a   Wasler, Andrä ^a   Khoschsorur, Gholam A ^b   Truschnig Wilders, Martie ^b   Tscheliessnigg, Karl Heinz ^a  

^a Department of Surgery   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

CYP3A5; Dose reduction; Genetic polymorphism; Heart transplantation

Indexed keywords

CYTOCHROME P450 3A5; EVEROLIMUS; TACROLIMUS;

ADULT; AGED; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HEART TRANSPLANTATION; HETEROZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL;

ADULT; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GRAFT REJECTION; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS; SIROLIMUS; TACROLIMUS;

EID: 79551708515     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01198.x     Document Type: Article

References (14)

1. Patel JK, Kobashigawa JA. Tacrolimus in heart transplant recipients: an overview. BioDrugs 2007: 21: 139.
2. McCormack PL, Keating GM. Tacrolimus: in heart transplant recipients. Drugs 2006: 66: 2269.
3. Eisen HJ, Tuzcu EM, Dorent R et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003: 349: 847.
4. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995: 29: 404.
5. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997: 54: 925.
6. Kamdem LK, Streit F, Zanger UM et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005: 51: 1374.
7. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004: 43: 83.
8. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001: 27: 383.
9. Xie HG, Wood AJ, Kim RB et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004: 5: 243.
10. Macphee IA, Fredericks S, Tai T et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002: 74: 1486.
11. Khoschsorur G. Simultaneous measurement of sirolimus and everolimus in whole blood by high-performance liquid chromatography with ultraviolet detection. Clin Chem 2005: 9: 1721.
12. Langsenlehner U, Krippl P, Renner W et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 2005: 90: 113.
13. Zheng H, Webber S, Zeevi A et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003: 3: 477.
14. Anglicheau D, Legendre C, Beaune P et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 2007: 8: 835.